Photodynamic therapy (PDT) and waterfiltered infrared A (wIRA) in patients with recalcitrant common hand and foot warts.
BACKGROUND
Common warts (verrucae vulgares) are human papilloma virus (HPV) infections with a high incidence and prevalence, most often affecting hands and feet, being able to impair quality of life. About 30 different therapeutic regimens described in literature reveal a lack of a single striking strategy. Recent publications showed positive results of photodynamic therapy (PDT) with 5-aminolevulinic acid (5-ALA) in the treatment of HPV-induced skin diseases, especially warts, using visible light (VIS) to stimulate an absorption band of endogenously formed protoporphyrin IX. Additional experiences adding waterfiltered infrared A (wIRA) during 5-ALA-PDT revealed positive effects.


OBJECTIVE
First prospective randomised controlled blind study including PDT and wIRA in the treatment of recalcitrant common hand and foot warts. Comparison of "5-ALA cream (ALA) vs. placebo cream (PLC)" and "irradiation with visible light and wIRA (VIS+wIRA) vs. irradiation with visible light alone (VIS)".


METHODS
Pre-treatment with keratolysis (salicylic acid) and curettage. PDT treatment: topical application of 5-ALA (Medac) in "unguentum emulsificans aquosum" vs. placebo; irradiation: combination of VIS and a large amount of wIRA (Hydrosun) radiator type 501, 4 mm water cuvette, waterfiltered spectrum 590-1400 nm, contact-free, typically painless) vs. VIS alone. Post-treatment with retinoic acid ointment. One to three therapy cycles every 3 weeks. Main variable of interest: "Percent change of total wart area of each patient over the time" (18 weeks). Global judgement by patient and by physician and subjective rating of feeling/pain (visual analogue scales). 80 patients with therapy-resistant common hand and foot warts were assigned randomly into one of the four therapy groups with comparable numbers of warts at comparable sites in all groups.


RESULTS
The individual total wart area decreased during 18 weeks in group 1 (ALA+VIS+wIRA) and in group 2 (PLC+VIS+wIRA) significantly more than in both groups without wIRA (group 3 (ALA+VIS) and 4 (PLC+VIS)): medians and interquartile ranges: -94% (-100%/-84%) vs. -99% (-100%/-71%) vs. -47% (-75%/0%) vs. -73% (-92%/-27%). After 18 weeks the two groups with wIRA differed remarkably from the two groups without wIRA: 42% vs. 7% completely cured patients; 72% vs. 34% vanished warts. Global judgement by patient and by physician and subjective rating of feeling was much better in the two groups with wIRA than in the two groups without wIRA.


CONCLUSIONS
The above described complete treatment scheme of hand and foot warts (keratolysis, curettage, PDT treatment, irradiation with VIS+wIRA, retinoic acid ointment; three therapy cycles every 3 weeks) proved to be effective. Within this treatment scheme wIRA as non-invasive and painless treatment modality revealed to be an important, effective factor, while photodynamic therapy with 5-ALA in the described form did not contribute recognisably - neither alone (without wIRA) nor in combination with wIRA - to a clinical improvement. For future treatment of warts an even improved scheme is proposed: one treatment cycle (keratolysis, curettage, wIRA, without PDT) once a week for six to nine weeks.
Fuchs
Silke M
SM
Department of Dermatology and Allergology, Friedrich Schiller University Hospital, Jena, Germany. Silke.Fuchs@med.uni-jena.de
Fluhr
Joachim W
JW
Bankova
Lora
L
Tittelbach
Jörg
J
Hoffmann
Gerd
G
Elsner
Peter
P
J Invest Dermatol. 1998 Oct;111(4):629-33
9764844
Lasers Surg Med. 2002;30(4):273-9
11948597
Cleve Clin Q. 1962 Jul;29:156-61
14466150
J Photochem Photobiol B. 2001 Aug 15;61(1-2):30-4
11485845
Dermatol Surg. 1998 Jul;24(7):723-6
9693665
Arch Dermatol. 1992 Jul;128(7):945-8
1626962
Skin Pharmacol Appl Skin Physiol. 2001;14 Suppl 1:10-6
11509901
Br J Cancer. 2003 Jul 21;89(2):405-11
12865936
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16024-8
12456879
Pharmazie. 2001 Oct;56(10):810-4
11683130
J Photochem Photobiol B. 1999 Mar;49(1):1-17
10365442
Br J Dermatol. 2001 Jan;144(1):4-11
11167676
Z Geburtshilfe Neonatol. 2000 May-Jun;204(3):85-92
10909163
J Cell Biol. 1991 Aug;114(3):493-502
1860881
Dermatol Surg. 1996 Dec;22(12):1035-8; discussion 1038-9
9078316
Photochem Photobiol Sci. 2004 Mar;3(3):263-7
14993942
Br J Dermatol. 1994 Jun;130(6):743-51
8011500
Lancet. 2000 Mar 18;355(9208):963-6
10768434
J Am Acad Dermatol. 2000 Mar;42(3):389-413; quiz 414-6
10688709
BMJ. 2002 Aug 31;325(7362):461
12202325
Lasers Surg Med. 2001;29(3):274-81
11573231
Int J Mol Med. 2000 Mar;5(3):247-51
10677564
J Photochem Photobiol B. 1990 Jun;6(1-2):143-8
2121931
J Photochem Photobiol B. 1996 Nov;36(2):213-9
9002264
Exp Dermatol. 2002 Aug;11(4):370-5
12190947
Dermatology. 1995;191(4):346-7
8573941
Photochem Photobiol. 1999 Apr;69(4):478-81
10212580
Adv Exp Med Biol. 1994;345:181-8
8079706
Ann Dermatol Venereol. 1998 Jul;125(6-7):443-62
9747307